Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 12/20 | 0.76 |
| ▸ | CCKAR | P32238 | 10/20 | 0.76 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.68 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.54 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8746534 | 0.86 | CCKAR (1.00) | CCKBRCCKARSCN9ANOTCH1RBPJ | |
| SCHEMBL9526556 | 0.86 | CCKAR (1.00) | CCKBRCCKARSCN9ANOTCH1RBPJ | |
| SCHEMBL8746538 | 0.86 | CCKAR (1.00) | CCKBRCCKARSCN9ANOTCH1RBPJ | |
| SCHEMBL9526550 | 0.86 | CCKAR (1.00) | CCKBRCCKARSCN9ANOTCH1RBPJ | |
| SCHEMBL5656206 | 0.86 | CCKBR (0.74) | CCKBRCCKAR | |
| SCHEMBL8774740 | 0.86 | CCKBR (0.74) | CCKBRCCKAR | |
| SCHEMBL644153 | 0.86 | CCKBR (0.74) | CCKBRCCKAR | |
| SCHEMBL9865746 | 0.86 | CCKBR (0.69) | CCKBRCCKARSCN9ANOTCH1RBPJ | |
| SCHEMBL10409010 | 0.83 | CCKBR (0.65) | CCKBRCCKARNOTCH1RBPJ | |
| SCHEMBL2539002 | 0.82 | CCKBR (0.90) | CCKBRCCKARSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119630-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | ARROW THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-7582624-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | GABRA6, CNR1, SIGMAR1 | CCKBR 195/4885CCKAR 137/4885SCN9A 600/4885 |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | GABRA6, CNR1, SIGMAR1 | CCKBR 197/4885CCKAR 137/4885SCN9A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.